Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
davelizomib + penpulimab
- Development stage
- Unknown
- Lead developer
- Chia Tai-Tianqing Pharmaceutical Group
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
TQB3602 + AK105 is a combination therapy consisting of davelizomib (TQB3602), an oral small-molecule proteasome inhibitor, and penpulimab (AK105), a humanized IgG1 monoclonal antibody targeting the programmed cell death protein 1 (PD-1) receptor. Developed by Chia Tai Tianqing (a subsidiary of Sino Biopharm) and Akeso Biopharma, this regimen is being evaluated for the treatment of advanced malignant solid tumors. Proteasome inhibition by davelizomib is intended to induce apoptosis in cancer cells and potentially enhance the immune response, while penpulimab acts as a checkpoint inhibitor to restore T-cell mediated anti-tumor activity. The combination is currently in Phase I clinical development.
- Brand names
- Anniko
- Other names
- TQB3602 + penpulimabdavelizomib + penpulimab
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)PSMB5 (Proteasome subunit beta Type-5)
Beyond the preview
Go deeper on davelizomib + penpulimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on davelizomib + penpulimab.